Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-gated sodium channel (VGSC) alpha subunits are the primary pore-forming components of sodium channels, responsible for the rapid influx of sodium ions that initiates and propagates action potentials in excitable tissues like the brain, heart, and skeletal muscle [1.2.1, 1.2.3]. In humans, there are nine distinct alpha subunit isoforms, designated Nav1.1 through Nav1.9, which are encoded by the SCN1A through SCN11A genes [1.1.5, 1.2.5]. These subunits are organized into four homologous domains, each containing six transmembrane segments that function as voltage sensors and the ion-selective pore [1.1.2, 1.3.2]. Dysregulation or mutations in these subunits lead to a wide range of channelopathies, including various forms of epilepsy, cardiac arrhythmias such as Brugada syndrome, and chronic pain disorders [1.2.2, 1.3.1]. Pharmacologically, these subunits are the primary targets for several classes of drugs, including local anesthetics, antiarrhythmics, and anticonvulsants, which typically act by binding to the inner pore and stabilizing the channel in an inactivated state [1.2.3, 1.2.4]. Current therapeutic development often aims for isoform-specific modulation to achieve efficacy in conditions like neuropathic pain while avoiding systemic side effects like cardiotoxicity [1.1.4, 1.3.2].
Drugs targeting the Nav1.x alpha subunit primarily act as pore blockers that bind to the local anesthetic receptor site within the S6 segments of the pore-forming domains [1.2.3]. They typically exhibit state-dependent binding, showing a higher affinity for the open or inactivated states of the channel, which leads to a frequency-dependent or use-dependent inhibition of sodium currents [1.2.4]. This mechanism effectively suppresses the high-frequency firing of action potentials in overactive neurons or myocytes while sparing normal electrical activity [1.2.2, 1.2.4].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated sodium channel alpha subunit (Nav1.x) (Nav1.x).